Surufatinib
Surufatinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target fibroblast growth factor receptor 1 and vascular endothelial growth factor receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
82 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 4 | 4 | 2 | — | 1 | 8 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | 2 | 1 | — | 2 | 4 |
| Neuroendocrine carcinoma | D018278 | — | — | 1 | 2 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 6 | 5 | — | — | — | 8 |
| Colorectal neoplasms | D015179 | — | — | 2 | 6 | — | — | — | 6 |
| Sarcoma | D012509 | — | — | 2 | 4 | — | — | — | 4 |
| Small cell lung carcinoma | D055752 | — | — | 2 | 4 | — | — | — | 4 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 4 | — | — | — | 4 |
| Osteosarcoma | D012516 | — | — | 2 | 3 | — | — | — | 3 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 2 | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 2 | — | — | — | 2 |
| Adenocarcinoma | D000230 | — | — | — | 2 | — | — | — | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 2 | — | — | — | 2 |
Show 19 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Surufatinib |
| INN | surufatinib |
| Description | Surufatinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target fibroblast growth factor receptor 1 and vascular endothelial growth factor receptor 2. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1 |
Identifiers
| PDB | — |
| CAS-ID | 1308672-74-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297190 |
| ChEBI ID | — |
| PubChem CID | 52920501 |
| DrugBank | DB15106 |
| UNII ID | B2K5L1L8S9 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
FGFR1
FGFR1
KDR
KDR
Organism
Homo sapiens
Gene name
FGFR1
Gene synonyms
BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR
NCBI Gene ID
Protein name
fibroblast growth factor receptor 1
Protein synonyms
Basic fibroblast growth factor receptor 1, bFGF-R-1, BFGFR, CD331, FGFR1/PLAG1 fusion, FLT-2, FMS-like tyrosine kinase 2, fms-related tyrosine kinase 2, heparin-binding growth factor receptor, hydroxyaryl-protein kinase, N-sam, Proto-oncogene c-Fgr
Uniprot ID
Mouse ortholog
Fgfr1 (14182)
fibroblast growth factor receptor 1 (Q9QZM7)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 258 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use